Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Ryouichi Tsunedomi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4251-1936; OpenAlex author ID A5002762936, A5029694147. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 10

  1. Reconsidering upfront surgery for resectable pancreatic ductal adenocarcinoma: The role of risk stratification and neoadjuvant chemotherapy. Co-author DOI 10.1016/j.suronc.2025.102333↗
  2. Immature Peritumoral Tertiary Lymphoid Structures Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After NAC. Co-author DOI 10.21873/anticanres.18061↗
  3. The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer. First author DOI 10.1111/cas.70087↗
  4. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers16142522↗
  5. The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers. Co-author DOI 10.1080/14737159.2023.2281482↗
  6. Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance. First author DOI 10.1097/mpa.0000000000001772↗
  7. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes. First author DOI 10.3892/ol.2020.12291↗
  8. Calreticulin is highly expressed in pancreatic cancer stem-like cells. Co-author DOI 10.1111/cas.13061↗
  9. Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates gr… Co-author DOI 10.1080/15384047.2014.1002357↗
  10. A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population. Co-author DOI 10.3892/ijo.2014.2603↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshitaro Shindo · 9 shared papers, 2014–2026 · strength 1.48
  2. Hiroaki Nagano · 7 shared papers, 2016–2026 · strength 1.21
  3. Hiroto Matsui Matsui · 7 shared papers, 2016–2026 · strength 1.21
  4. Tatsuya Ioka · 5 shared papers, 2021–2026 · strength 1.05
  5. Masao Nakajima · 4 shared papers, 2023–2026 · strength 0.94
  6. Hidenori Takahashi · 3 shared papers, 2024–2026 · strength 0.69
  7. Yusaku Watanabe · 4 shared papers, 2014–2026 · strength 0.52
  8. Satoshi Matsukuma · 3 shared papers, 2016–2021 · strength 0.26
  9. Mari Nabeya · 1 shared paper, 2026 · strength 0.26
  10. Nobuaki Suzuki · 3 shared papers, 2014–2021 · strength 0.25
  11. Hirofumi Akita · 1 shared paper, 2025 · strength 0.25
  12. Gen Kanesada · 1 shared paper, 2025 · strength 0.25
  13. Hiroaki Nagano · 1 shared paper, 2023 · strength 0.24
  14. Yasuhiro Fujiwara · 2 shared papers, 2021 · strength 0.22
  15. Hidetoshi Eguchi · 2 shared papers, 2016–2021 · strength 0.15
  16. Masaaki Oka · 3 shared papers, 2014–2016 · strength 0.12
  17. Takuya Fujimoto · 1 shared paper, 2021 · strength 0.11
  18. Sonshin Takao · 1 shared paper, 2015 · strength 0.05
  19. Susumu Ishiguro · 1 shared paper, 2015 · strength 0.05
  20. Masaaki Tamura · 1 shared paper, 2015 · strength 0.05
  21. Tomio Ueno · 1 shared paper, 2016 · strength 0.04
  22. Koji Tamada · 1 shared paper, 2014 · strength 0.03
  23. Hideyuki Saya · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.